Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Natl Cancer Inst ; 91(17): 1487-91, 1999 Sep 01.
Article in English | MEDLINE | ID: mdl-10469750

ABSTRACT

BACKGROUND: African-American women with breast cancer have poorer survival than European-American women. After adjustment for socioeconomic variables, survival differences diminish but do not disappear, possibly because of residual differences in health care access, biology, or behavior. This study compared breast cancer survival in African-American and European-American women with similar health care access. METHODS: We measured survival in women with breast cancer who are served by a large medical group and a metropolitan Detroit health maintenance organization where screening, diagnosis, treatment, and follow-up are based on standard practices and mammography is a covered benefit. We abstracted data on African-American and European-American women who had been diagnosed with breast cancer from January 1986 through April 1996 (n = 886) and followed these women for survival through April 1997 (137 deaths). RESULTS: African-American women were diagnosed at a later stage than were European-American women. Median follow-up was 50 months. Five-year survival was 77% for African-American and 84% for European-American women. The crude hazard ratio for African-American women relative to European-American women was 1.6 (95% confidence interval [CI] = 1.1-2.2). Adjusting only for stage, the hazard ratio was 1.3 (95% CI = 0.9-1.9). Adjusting only for sociodemographic factors (age, marital status, and income), the hazard ratio was 1.2 (95% CI = 0.8-1.9). After adjusting for age, marital status, income, and stage, the hazard ratio was 1.0 (95% CI = 0.7-1.5). CONCLUSION: Among women with similar medical care access since before their diagnoses, we found ethnic differences in stage of breast cancer at diagnosis. Adjustment for this difference and for income, age, and marital status resulted in a negligible effect of race on survival.


Subject(s)
Black or African American/statistics & numerical data , Breast Neoplasms/ethnology , Breast Neoplasms/mortality , Managed Care Programs/statistics & numerical data , White People/statistics & numerical data , Adult , Age Factors , Aged , Breast Neoplasms/diagnosis , Female , Health Services Accessibility , Humans , Income , Marital Status , Michigan/epidemiology , Middle Aged , Odds Ratio , Survival Rate , Urban Health
2.
Cytometry ; 31(1): 67-73, 1998 Jan 01.
Article in English | MEDLINE | ID: mdl-9450527

ABSTRACT

This is a report from the Kananaskis working group on quantitative methods in tumour heterogeneity. Tumour progression is currently believed to result from genetic instability and consequent acquisition of new genetic properties in some of the tumour cells. Cross-sectional assessment of genetic markers for human tumours requires quantifiable measures of intratumour heterogeneity for each parameter or characteristic observed; the relevance of heterogeneity to tumour progression can best be ascertained by repeated assessment along a tumour progressional time line. This paper outlines experimental and analytic considerations that, with repeated use, should lead to a better understanding of tumour heterogeneity, and hence, to improvements in patient diagnosis and therapy. Four general principles were agreed upon at the Symposium: (1) the concept of heterogeneity requires a quantifiable definition so that it can be assessed repeatably; (2) the quantification of heterogeneity is necessary so that testable hypotheses may be formulated and checked to determine the degree of support from observed data; (3) it is necessary to consider (a) what is being measured, (b) what is currently measurable, and (c) what should be measured; and (4) the proposal of working models is a useful step that will assist our understanding of the origins and significance of heterogeneity in tumours. The properties of these models should then be studied so that hypotheses may be refined and validated.


Subject(s)
Genetic Heterogeneity , Genetic Markers , Neoplasms/genetics , Disease Progression , Evaluation Studies as Topic , Humans , Neoplasms/pathology , Reproducibility of Results
3.
FASEB J ; 11(7): 535-43, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9212077

ABSTRACT

Research in breast cancer extends in many directions, stimulated by concerns related to the high incidence of the disease and the relative unpredictability of its clinical course. Examples of work in several directions are presented here arranged by four levels of analysis. 1) Molecular, intracellular events (molecular genetics). Recent identification of genes that predispose to breast cancer, and the isolation of those genes and their protein products, permit investigations of the most critical issues: the roles of these genes in normal development and breast differentiation, and how their alteration permits or contributes to tumor initiation. Thus, we expect that understanding the functions of the genes involved in inherited susceptibility to breast cancer will also be informative for sporadic breast cancers. 2) Cellular biology (cellular models for preneoplastic disease). We examine models of breast cancer development and ask how they help to validate a morphologic sequence for human breast neoplasia and whether they permit investigation of how to modify disease progression. Two useful models, one in transgenic mice and the other using human breast stem cells capable of culture and xenograft growth, are now available. 3) Tissue and organ (the tumor and its local environment). We look at the relationship of the tumor cell population to its local environment (stroma, blood vessels, etc.). This leads naturally to questions of how neighboring tissues and cytokines may modify tumor growth. 4) The individual as an organism and member of a population (hormonal rise and chemoprevention). We address identification of the primarily hormonal risk factors and a possible related mode of cancer prevention.


Subject(s)
Breast Neoplasms , Animals , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Breast Neoplasms/prevention & control , Chemoprevention , Disease Models, Animal , Female , Humans , Mice , Research
4.
Med Decis Making ; 14(4): 345-56, 1994.
Article in English | MEDLINE | ID: mdl-7808209

ABSTRACT

In a clinical trial to increase the screening of inner-city women for breast cancer, some preliminary data suggested that about 40% of the age-eligible women who had been patients at a primary-care clinic might be expected never to visit that clinic again. The distribution of time between patients' clinic visits was modeled by fitting a distribution function to data on the "time to first visit," and indicated that the true defection rate is probably around 31 to 36%. This result, which is consistent with four related observations, suggests that most of the patients who fail to visit their clinics in a year-long interval may have become clients of other clinics. This conjecture implies massive continuing exchanges of patients among clinics, and may mean that explicit outreach by mail or phone to "non-visiting clients" will add few patient contacts to those based on spontaneous clinic visits.


Subject(s)
Breast Neoplasms/prevention & control , Health Behavior , Mass Screening/statistics & numerical data , Models, Statistical , Patient Acceptance of Health Care/statistics & numerical data , Primary Health Care/statistics & numerical data , Treatment Refusal , Black or African American , Female , Humans , Markov Chains , Michigan
SELECTION OF CITATIONS
SEARCH DETAIL
...